Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Multicompartment Models: Overview01:14

Multicompartment Models: Overview

Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs01:21

Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs

The fundamental mathematical principles, such as calculus and graphs, play crucial roles in analyzing drug movement and determining pharmacokinetic parameters. Differential calculus examines rates of change and helps to determine the dissolution rate of drugs in biofluids, as well as how drug concentrations change over time. For instance, it can help calculate the rate of elimination of a drug from the body based on its concentration-time profile.
On the other hand, integral calculus focuses on...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling calcium-dependent passive cardiac mechanics in the mouse.

Acta biomaterialia·2026
Same author

Molecular systems architecture of host-microbiome interactions in periodontitis.

JADA foundational science·2026
Same author

Beyond Diagnosis: Evaluating Multimodal LLMs for Pathology Localization in Chest Radiographs.

Proceedings of machine learning research·2026
Same author

A molecular systems architecture of asthma.

Frontiers in immunology·2026
Same author

In silico evaluation of cardiac tissue-engineered patch interventions.

Computers in biology and medicine·2025
Same author

A molecular systems architecture of the mesenchymal stromal cell microenvironment.

Stem cells (Dayton, Ohio)·2025
Same journal

Enhancing Volumetric Imaging in Linear-Array Photoacoustic Tomography: multiview fusion with deep learning.

IEEE transactions on bio-medical engineering·2026
Same journal

Robust Rule-based Heuristic Assistance Strategy for a Semi-Active Shoulder Exoskeleton Used in Overhead Work.

IEEE transactions on bio-medical engineering·2026
Same journal

Highly Accelerated 1-mm Isotropic 3D Chemical Exchange Saturation Transfer MRI Using Wave-Co-CAIPI at 5 Tesla.

IEEE transactions on bio-medical engineering·2026
Same journal

Systematic Evaluation of Hip Exoskeleton Assistance Parameters for Enhancing Gait Stability During Ground Slip Perturbations.

IEEE transactions on bio-medical engineering·2026
Same journal

SleepConFormer: A Single-Channel EEG Framework for Sleep Staging and Consciousness Assessment in Patients with Disorders of Consciousness.

IEEE transactions on bio-medical engineering·2026
Same journal

Modeling Partial and Total Support of Left Ventricular Assist Device for Discrete Hemodynamic Control Framework.

IEEE transactions on bio-medical engineering·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Multiscale mathematical modeling to support drug development.

David A Nordsletten1, Beracah Yankama, Renato Umeton

  • 1King’s College, London, SE1 8WA, UK. david.nordsletten@googlemail.com

IEEE Transactions on Bio-Medical Engineering
|November 2, 2011
PubMed
Summary
This summary is machine-generated.

Multiscale mathematical pathway modeling can accelerate drug development timelines and improve the success rates of new therapeutic drugs entering clinical trials. This approach addresses the complexity of biological systems to enhance drug discovery efficiency.

Related Experiment Videos

Last Updated: May 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

  • Computational biology
  • Pharmacology
  • Drug discovery

Background:

  • Current drug development is lengthy (10-14 years) and costly (hundreds of millions USD).
  • High attrition rates persist, with only 30-40% of drug candidates succeeding in clinical trials.
  • Significant improvements are needed in existing therapeutic drug development methodologies.

Purpose of the Study:

  • To propose multiscale mathematical pathway modeling as a solution to enhance drug development.
  • To reduce the time from target identification to clinical trial.
  • To increase the success probability of drug candidates in human trials.

Main Methods:

  • Development and application of multiscale mathematical pathway models.
  • Analysis of requirements for modeling across multiple temporal and spatial scales.
  • Identification of novel computational paradigms for complex biological system modeling.

Main Results:

  • Proposed modeling approach can decrease drug development timelines.
  • Enhanced modeling strategies can improve the likelihood of clinical trial success.
  • Identified computational paradigms to handle multiscale modeling complexities.

Conclusions:

  • Multiscale mathematical pathway modeling offers a promising strategy to optimize drug discovery.
  • This approach has the potential to significantly reduce costs and timelines in pharmaceutical development.
  • Addressing multiscale requirements is crucial for advancing computational drug development.